Año 2023 / Volumen 115 / Número 6
Carta
Efficacy and safety of intravenous ustekinumab maintenance therapy in Crohn’s disease.

340-341

DOI: 10.17235/reed.2023.9594/2023

Benito Hermida Pérez, Alejo Mancebo Mata, Miguel Ángel de Jorge Turrión, Pilar Varela Trastoy,

Resumen
Crohn’s disease is a chronic multifactorial disease for which therapeutic options have expanded in the last decades. However there are still patients who lack or lose response to current standard treatment strategies. A unicentric, retrospective, study was performed in order to evaluate the clinical and biochemical response to intravenous ustekinumab manteinance therapy (IVUMT) in patients with refractory CD. We included 12 patients from our centre who started IVUMT between September 2018 and November 2021. 75% started IV treatment after previous subcutaneous (SC) treatment. At week 8 (n=8), 63% had clinical response, with 25% in clinical remission. At week 16 (n=10), 60% had clinical response, with 50% in clinical remission. At week 26 (n=10), 90% had clinical response, with 60% in clinical remission. At week 52 (n=11), 91% had clinical response, with 64% in clinical remission (Fig. 2). Basal faecal calprotectin (FCP) median level was 684µg/g, with a significant reduction at 52 weeks, with median FCP 97µg/g (p=0,017). Basal C-reactive protein (CRP) median level was 11,6mg/L. A significant reduction was observed at week 26, with median CRP 2,8mg/L (p=0,008); and 52 weeks, with median CRP 2,7 (p=0,013). Average follow-up was 117,1 weeks, average treatment survival was 105,9 weeks. There were no severe adverse events. Our results suggest IVUMT is a safe and effective treatment for most patients with refractory and complex CD and should be considered as an option in selected patients.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
Ollech JE, Normatov I, Peleg N, et al. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2021 Jan;19(1):104–10.
Dalal RS, Njie C, Marcus J, et al. Predictors of Ustekinumab Failure in Crohn’s Disease After Dose Intensification. Inflamm Bowel Dis. 2021 Jul 27;27(8):1294–301.
Kopylov U, Hanzel J, Liefferinckx C, et al. Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. Aliment Pharmacol Ther. 2020 Jul;52(1):135–42.
Fumery M, Peyrin-Biroulet L, Nancey S, et al. Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn’s Disease: A Multicenter Study. J Crohns Colitis. 2020 Sep 8;jjaa177.
Srinivasan A, van Langenberg D, De Cruz P. Real-World Effectiveness of Ustekinumab Dose Intensification in Crohn’s Disease. Inflammatory Bowel Diseases. 2021 Jun 1;27(6):e69.
Sedano R, Guizzetti L, McDonald C, et al. Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn’s Disease Patients Already on Every-4-Week Dosing. Clin Gastroenterol Hepatol. 2021 Jul;19(7):1497-1498.e1.
Bermejo F, Jiménez L, Algaba A, et al. Re-induction With Intravenous Ustekinumab in Patients With Crohn’s Disease and a Loss of Response to This Therapy. Inflamm Bowel Dis. 2022 Jan 5;28(1):41–7.
Meserve J, Ma C, Dulai PS, et al. Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022 Dec;20(12):2728-2740.e1
Pérez Valle I, Varela Trastoy P, Mancebo Mata A. Preliminary experience of maintenance treatment with intravenous ustekinumab as a rescue treatment for loss of response to subcutaneous doses. Rev Esp Enferm Dig. 2021 Mar;113(3):186–8.
Artículos relacionados

Editorial

Redes sociales online y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2018.5496/2018

Instrucciones para citar
Hermida Pérez B, Mancebo Mata A, de Jorge Turrión M, Varela Trastoy P. Efficacy and safety of intravenous ustekinumab maintenance therapy in Crohn’s disease.. 9594/2023


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1373 veces.
Este artículo ha sido descargado 220 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 13/03/2023

Aceptado: 15/03/2023

Prepublicado: 28/03/2023

Publicado: 06/06/2023

Tiempo de prepublicación: 15 días

Tiempo de edición del artículo: 85 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas